Drugs / Ceftolozane/Tazobactam
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03830333 | Mar 2019 → Oct 2020 | — | Merck Sharp & Dohme LLC | Completed | Met primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2015-04-27 | Merck Sharp & Dohme LLC | Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA™ (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases merck.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ceftolozane/Tazobactam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03830333 ↗ |
| Route | Intravenous | “Ceftolozane 1000 mg / tazobactam 500 mg by IV infusion every 8 hours for 4 to 14 days.” NCT03830333 ↗ |